Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Why?

Strongest counted support: The trial found no significant intention-to-treat cure difference, a per-protocol final-cure advantage for drug treatment, and no serious adverse events. weight 1.800000 evidence

Suppressed as dependent: The packet directly supports the sample, intention-to-treat comparison, per-protocol result, and absence of serious adverse events.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Leans supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In an Ethiopian phase II randomized trial of 183 adults with localized Leishmania aethiopica cutaneous leishmaniasis, single-session thermotherapy and weekly...” · 1 claim · 29 September 2026
• “In an Ethiopian phase II randomized trial of 183 adults with localized Leishmania aethiopica cutaneous leishmaniasis, single-session thermotherapy and weekly...” · 1 claim · 29 September 2026

Evidence for

• The trial found no significant intention-to-treat cure difference, a per-protocol final-cure advantage for drug treatment, and no serious adverse events.

  From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

• The packet directly supports the sample, intention-to-treat comparison, per-protocol result, and absence of serious adverse events.

  From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

• Independent reporting reproduces the trial’s intention-to-treat comparability and per-protocol advantage for intralesional sodium stibogluconate.

  From Single-Session Heat Treatment Matches Standard Drug Therapy for Disfiguring Skin Disease in Ethiopia Read 2026-09-29 Relevance STRONG Steps 0 Counted

  Secondary report also describes the 183-participant Ethiopian trial and its safety/adherence context.

Evidence against

None.

Qualifications

• The comparison applies to adults with uncomplicated localized parasitologically confirmed disease and specified regimens assessed at day 90/105 and day 180.

  From Thermotherapy compared with intralesional sodium stibogluconate for Leishmania aethiopica cutaneous Leishmaniasis in Ethiopia: A phase II randomized controlled trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Adds eligibility, treatment dosing, and endpoint timing/analysis scope.

Suppressed as dependent

Evidence	Group	Kept instead
30879a77		28ae72b7

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	f3e8f5bc, 28ae72b7, 434d220c

Summary

Contribution history

seq	event	detail
17975	APPENDED
17976	ACCEPT	AUTOMATIC_AFTER_VALIDATION
17981	LINK_EVIDENCE	by 1efd24fe (accepted)
17983	TASK_RESULT	by 1efd24fe (accepted)
18005	LINK_EVIDENCE	by 1efd24fe (accepted)
25377	TASK_RESULT	by 1efd24fe (accepted)